google-site-verification: google28f501b00d980d5f.html New Trial Results Prove MSD Animal Health’s Equilis® Prequenza Delivers Optimal Protection from Equine Influenza - Vetpol Community


No announcement yet.

New Trial Results Prove MSD Animal Health’s Equilis® Prequenza Delivers Optimal Protection from Equine Influenza


  • New Trial Results Prove MSD Animal Health’s Equilis® Prequenza Delivers Optimal Protection from Equine Influenza

    Click image for larger version

Name:	Group mean virus excretion.jpg
Views:	47
Size:	108.0 KB
ID:	47186

    New comparative efficacy trial results prove that MSD Animal Health’s Equilis® Prequenza offers highly significant protection against viral shedding and the clinical signs of equine influenza (EI).

    Current OIE recommendations are to include a representative strain from each of the two sublineages of equine influenza virus (EIV) - Florida Clade 1 and Florida Clade 2, to deliver optimum protection. The study1by MSD Animal Health Equine was designed to evaluate the efficacy of Equilis Prequenza, containing whole virus Newmarket/2/93 (European strain) and South Africa/4/03 (Clade1) EIV strains, and an HA canarypox vectored vaccine containing Florida Clade 1 and Clade 2 strains. The study was carried out using experimental infection with Wexford/14, a recent FloridaClade2 strain of equine influenza virus, during the immunity gap.

    Vicki Farr, BVetMed MRCVS, equine veterinary advisor at MSD Animal Health comments:
    “Following challenge at 120 days after V2 with Wexford/14, this study demonstrates that both vaccines provide a highly significant degree of protection against clinical signs of EI and viral shedding compared to unvaccinated controls. Although the study was not designed to compare the efficacy of the two vaccines, because of practical limitations on the number of animals and hence low power, there was no evidence of any significant differences between these two groups. There was, however, a trend towards slightly lower clinical score on days 4-8 and reduced virus excretion on days 2-5 in the Equilis Prequenza group compared to the HA canarypox vectored vaccine.”

    Equilis Prequenza offers a broad based approach to immunogenicity by addressing and adapting key areas of an equine influenza vaccine - Matrix-C adjuvant, whole virus antigen and strain. Efficacy has been proven through challenge trials and longer term protection confirmed by serology.

    Vicki Farr adds: “Equilis Prequenza addresses key factors involved in promoting effective immunogenicity. It combines the demonstrated efficacy against challenge, with a current circulating strain with an established safety profile. Equilis Prequenza stimulates active immunity against EI providing the reassurance your clients demand. MSD Animal Health is committed to working with equine practices to improve vaccination rates in at-risk horses.”

    EI is a viral disease that affects horses, donkeys and mules. It is endemic in nearly every country in the world and is rapidly transmitted from horse to horse by direct and indirect contact, for example, via contaminated feed buckets, tack and human clothes. It is highly infectious and can have serious implications for equine health and devastating economic losses through disruption to horse movements, trade and competition. Experts agree that the best way to protect is by vaccination.

    For more information about the trial results contact your MSD Animal Health account manager.

    1Two groups of seven Fjord ponies were vaccinated twice,4 weeks apart (V1 on day 0 and V2 on day 28). One group was vaccinated with Equilis Prequenza (MSD AH) and one group with ProteqFlu (Boehringer Ingleheim).

    The protective antibody response was measured and ponies were challenged, along with six unvaccinated control ponies, by experimental infection with Wexford/14 (a heterologous clade 2 strain), 120 days (4.5 months) after V2, and clinical signs and virus shedding monitored. EI serology was measured by single radial haemolysis (SRH) and hemagglutination inhibition (HI). Clinical signs and virus shedding (measured by qRT-PCR and egg titration) were compared between groups and with controls.
    Attached Files
    Last edited by Jo Kitson; 01-10-2018, 12:40 PM.
      Posting comments is disabled.



    Article Tags


    Latest Articles


    • Zoetis UK Ltd – We Have Moved
      by Kristina Kisbee

      Zoetis Ltd would like to let those of you who may not know we have moved to a new office location. As of the 17th June our new home is;

      Zoetis UK Ltd, First Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP

      It is an exciting move which sees us set up in a brand-new office space. A new space that is much appreciated as we continue to grow our teams to support our evolving range of products and solutions we offer across the continuum of care....
      Today, 01:02 PM
    • Davies Green Team takes action for World Environment Day
      by Kristina Kisbee

      The enthusiastic Green Group at Davies Veterinary Specialists (Davies), Hertfordshire got stuck in to World Environment Day last week, as part of their continual commitment to sustainability in practice. As well as encouraging staff to make pledges, calculate their own carbon footprints, and pedal to make smoothies, they unveiled a pet owner newsletter to make suggestions on green pet ownership and offered reusable water bottles to clients seen at Davies on June 5th.

      Today, 09:24 AM
    • Purina reveals a revolutionary approach to managing cat allergens
      by Kristina Kisbee

      For the first time in history, Purina scientists demonstrate a proactive way to significantly reduce the active levels of the major cat allergen, Fel d1, at its source in cats’ saliva. As many as one in five adults worldwide are sensitised to cat allergens.

      Avoiding cats is a cornerstone of managing allergens, an approach that may leave cats looking for a new home. Taking advantage of natural allergen-antibody interactions, Purina researchers discovered how to safely
      Today, 09:20 AM
    • Vets urged to THINK TWICE this Dry Eye Awareness Month
      by Kristina Kisbee

      Ocular conditions account for around one in ten canine consultations in first opinion practices1 and in the lead up to Dry Eye Awareness Month, Bayer are asking vets to think twice about their approach to Dry Eye management.

      In the case of KCS, early diagnosis and treatment can have a significant impact on prognosis, but unfortunately, 46% of dog owners are not aware of the risks.2 Some KCS cases may present with quite mild clinical signs, particularly in the early stages
      14-06-2019, 07:07 AM
    • Record-breaking VET Festival Champions Wellness
      by Kristina Kisbee

      Notching up record delegate and exhibitor numbers for 2019, this year’s VET Festival, received an overwhelmingly positive response from delegates for the calibre of speakers and entertainment. The event took place at Loseley Park, Guildford on 7-8 June.

      With wellness a strong focus for VET Festival, the Wellness lecture tent was packed for Lara Heimann, an American who has achieved global recognition for her unique vinyasa yoga style and regularly leads international
      14-06-2019, 07:06 AM
    • Vetsure launch new Large Animal and Equine Buysure Platinum buying group services
      by Kristina Kisbee

      Since their inception 10 years ago, Vetsure have been offering market-leading purchase savings to all practice types through their Buysure for Vets and Buysure Platinum buying groups. Until recently, however, their Platinum offering – whereby members benefit from corporate terms in return for use of preferred products – has been limited to small animal practices. That has all changed now with the launch of the LA/Equine Buysure Platinum Group.

      “There is considerable disruption
      13-06-2019, 11:51 AM